Sharekhan's research report on Insecticides (India)
In-line operating profit of Rs. 58 crore (up 10% q-o-q) as stronger-than-expected revenue growth of 20% y-o-y was offset by a miss in margins. PAT of Rs. 38 crore (up 9.6% y-o-y) was 2% above our estimate due to lower-than-expected tax rate. Strong revenue growth was led by 21%/31% y-o-y revenue growth from B2C/B2B business. OPM miss of 87 bps was due to lower-than-expected gross margin and FX loss of Rs. 6.5 crore. Adjusted OPM of 11.6% was slightly better than our estimate of 11.3%. Management maintained its double-digit (18-20% y-o-y) revenue growth and margin guidance of a 100 bps rise for FY23. It expects a similar growth momentum in FY24. However, the company lowered export revenue guidance by 25% to Rs. 150 crore.
Outlook
We maintain a Buy on Insecticides (India) Limited with a revised PT of Rs. 1,170 as we expect a strong 34% PAT CAGR over FY22-FY24E. Valuation of 13.7x/10.4x its FY2023E/FY2024E EPS is attractive.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest business news, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!